FDA Approves LENZ Eye Drop for Presbyopia

The FDA has approved LENZ Therapeutics’ VIZZ, an aceclidine ophthalmic solution, marking it as the first FDA-approved eye drop for presbyopia in adults. Presbyopia, a condition causing blurred vision due to aging, affects approximately 128 million people in the U.S. This approval represents a significant advancement in treatment options for this widespread condition. VIZZ, previously known as LNZ100, offers a new non-surgical option for those experiencing age-related vision changes. The approval could potentially lead to increased market activity for LENZ Therapeutics and provide a new avenue for addressing presbyopia, which has long been a challenge for the aging population.